The main purpose of this study is to evaluate how the body processes the study drug known as insulin peglispro and how the study drug affects blood sugar in healthy male Japanese participants. This study will also evaluate safety of the study drug. The study will last up to 46 days for each participant, not including screening.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
11
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukuoka, Japan
Pharmacokinetics: Observed Maximum Concentration (Cmax) of Insulin Peglispro
Time frame: Predose and 2, 4, 8, 12, 24, 30, 36, 48, 96, 144, and 192 hours postdose
Pharmacokinetics: Area Under the Concentration Curve (AUC) of Insulin Peglispro
AUC from time zero to infinity (AUC\[0-∞\]) of insulin peglispro was evaluated.
Time frame: Predose and 2, 4, 8, 12, 24, 30, 36, 48, 96, 144, and 192 hours postdose
Pharmacokinetics: Time of Maximum Observed Drug Concentration (Tmax) of Insulin Peglispro
Time frame: Predose and 2, 4, 8, 12, 24, 30, 36, 48, 96, 144, and 192 hours postdose
Glucodynamics: Maximum Glucose Infusion Rate (Rmax)
Time frame: Predose up to 36 hours post clamp procedure
Glucodynamics: Total Amount of Glucose Infused (Gtot)
Time frame: Predose up to 36 hours post clamp procedure.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.